Pneumologie 2019; 73(S 01)
DOI: 10.1055/s-0039-1678042
Posterbegehung (P05) – Sektion Klinische Pneumologie
Asthma 2019
Georg Thieme Verlag KG Stuttgart · New York

Tiotropium provides greater improvements in FEV1 than leukotriene receptor antagonists as add-on to ICS in adults with asthma: a systematic review

on behalf of
E Beck
1   Institut für Gesundheitsförderung, Rüdersdorf, Brandenburg,
,
A Kaplan
2   Family Physician Airways Group of Canada, University of Toronto, Family Physician Airways Group of Canada
,
JM Fitzgerald
3   The Lung Centre, Gordon and Leslie Diamond Health Care Centre; University of British Columbia
,
GE Azzi
4   Ta Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. Kg
,
M Engel
4   Ta Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. Kg
,
R Buhl
5   Universitätsmedizin Mainz, Med. Klinik III, Schwerpunkt Pneumologie
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
19. Februar 2019 (online)

Auch verfügbar auf
 
 

    Introduction Adults with asthma who are not controlled on inhaled corticosteroids (ICS) may be treated with tiotropium or leukotriene receptor antagonists (LTRAs), such as montelukast or zafirlukast, as add-on therapies.

    Aim In this systematic literature search we compared the efficacy of tiotropium and LTRAs as add-on to ICS in adult patients with asthma.

    Methods We searched PubMed for publications that compared tiotropium or LTRAs with placebo, as add-on to ICS, for at least 4 weeks, reporting change in forced expiratory volume in 1 second (FEV1) or number of exacerbations requiring oral corticosteroids (OCS).

    Results The systematic literature search identified four relevant publications: a tiotropium meta-analysis, two montelukast randomised controlled trials (RCTs) and a zafirlukast RCT. Overall, tiotropium had a greater effect on FEV1 than LTRAs. Mean change in FEV1 from baseline versus placebo was 0.14 – 0.19 L with tiotropium, 0.03 – 0.10 L with montelukast and 0.12 L with zafirlukast. Exacerbations requiring OCS were significantly reduced with tiotropium, but not montelukast, versus placebo. Exacerbations requiring additional controller therapy (70% of therapies were OCS) were significantly reduced with zafirlukast versus placebo.

    Conclusion This systematic literature review suggests that tiotropium provides greater improvements in FEV1 than montelukast or zafirlukast as an add-on to ICS in adults with asthma.


    #